Working… Menu

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04830397
Recruitment Status : Recruiting
First Posted : April 5, 2021
Last Update Posted : June 15, 2021
Information provided by (Responsible Party):
Qlaris Bio, Inc.

Brief Summary:
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.

Condition or disease Intervention/treatment Phase
Primary Open Angle Glaucoma Ocular Hypertension Drug: QLS-101 Drug: Timolol Maleate Phase 2

Detailed Description:
Multi-site study to evaluate the safety and tolerability of 3 concentrations of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Active-controlled Multi-site Double-masked Study to Evaluate the Safety and Tolerability of 3 Concentrations of QLS-101 Versus Timolol Maleate Preservative Free (PF) 0.5% Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
Actual Study Start Date : March 31, 2021
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: QLS-101 0.5% Drug: QLS-101
Ophthalmic solution 1x daily

Experimental: QLS-101 1% Drug: QLS-101
Ophthalmic solution 1x daily

Experimental: QLS-101 2% Drug: QLS-101
Ophthalmic solution 1x daily

Active Comparator: Timolol Maleate 0.5% preservative free ophthalmic solution Drug: Timolol Maleate
Ophthalmic solution 1x daily

Primary Outcome Measures :
  1. Ocular safety [ Time Frame: 100 days ]
    Number of participants with treatment-related adverse events will be monitored

Secondary Outcome Measures :
  1. Ocular hypotensive efficacy [ Time Frame: 28 days ]
    Number of participants with intraocular pressure reduction from baseline will be calculated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Visual acuity +1.0 logMAR or better
  2. Willing to give informed consent
  3. Ability to washout from current intraocular pressure lowering medications -

Exclusion Criteria:

  1. Severe glaucomatous damage
  2. Previous glaucoma intraocular or laser surgery
  3. Refractive surgery
  4. Ocular infection or inflammation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04830397

Layout table for location contacts
Contact: Cheryl St John 508-514-9034
Contact: Lisa Brandano 978-930-2103

Layout table for location information
United States, Georgia
Dixon Eye Care Recruiting
Albany, Georgia, United States, 31701
Sponsors and Collaborators
Qlaris Bio, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Qlaris Bio, Inc. Identifier: NCT04830397    
Other Study ID Numbers: QC-201
First Posted: April 5, 2021    Key Record Dates
Last Update Posted: June 15, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Qlaris Bio, Inc.:
elevated intraocular pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents